Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 0.97 |
| ▸ | RCOR1 | Q9UKL0 | 12/20 | 0.97 |
| ▸ | MAOA | P21397 | 8/20 | 0.57 |
| ▸ | MAOB | P27338 | 8/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15787696 | 1.00 | KDM1A (0.97) | KDM1ARCOR1MAOAMAOB | |
| SCHEMBL15766948 | 1.00 | KDM1A (0.97) | KDM1ARCOR1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL17223489 | 0.98 | KDM1A (1.00) | KDM1ARCOR1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL17223491 | 0.98 | KDM1A (1.00) | KDM1ARCOR1MAOAMAOB | |
| SCHEMBL17231234 | 0.81 | KDM1A (0.66) | KDM1ARCOR1MAOAMAOB | |
| SCHEMBL15787380 | 0.80 | KDM1A (0.97) | KDM1ARCOR1MAOAMAOB | |
| SCHEMBL15767422 | 0.80 | KDM1A (0.97) | KDM1ARCOR1MAOAMAOB | |
| SCHEMBL15767423 | 0.80 | KDM1A (0.97) | KDM1ARCOR1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL17223530 | 0.78 | KDM1A (1.00) | KDM1ARCOR1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL22318600 | 0.78 | KDM1A (1.00) | KDM1ARCOR1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928457-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-08-12 | — | — | EP | claimed |
| US-9944589-B2 | Cycloproplyamine derivatives useful as inhibitors of histone demethylases KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2018-04-17 | — | — | US | claimed |
| US-20150315126-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2015-11-05 | — | — | US | claimed |
| EP-2928457-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | Istituto Europeo di Oncologia S.r.l. (IT) | 2015-10-14 | — | — | EP | claimed |
| WO-2014086790-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2014-06-12 | — | — | WO | claimed |
| EP-2740474-A1 | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a | Instituto Europeo di Oncologia S.r.l. (IT) | 2014-06-11 | — | — | EP | claimed |
| US-12576083-B2 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2026-03-17 | — | — | US | disclosed |
| US-20240342178-A1 | COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2024-10-17 | — | — | US | disclosed |
| US-11918580-B2 | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20210100800-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | INSTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-04-08 | — | — | US | disclosed |
| EP-2928457-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-08-12 | — | — | EP | disclosed |
| WO-2018197583-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2018-11-01 | — | — | WO | disclosed |
| US-20180311245-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH CDK2 INHIBITORS IN THE TREATMENT OF CANCER | RASNA THERAPEUTICS LTD (GB) | 2018-11-01 | — | — | US | disclosed |
| US-9944589-B2 | Cycloproplyamine derivatives useful as inhibitors of histone demethylases KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2018-04-17 | — | — | US | disclosed |
| WO-2017097865-A9 | COMBINATION OF CALORIC RESTRICTION (CR) OR IGF1/INSULIN RECEPTOR INHIBITOR WITH LSD1 INHIBITOR | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017097865-A1 | COMBINATION OF CALORIC RESTRICTION (CR) OR IGF1/INSULIN RECEPTOR INHIBITOR WITH LSD1 INHIBITOR | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2017-06-15 | — | — | WO | disclosed |
| US-20150315126-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2015-11-05 | — | — | US | disclosed |
| EP-2928457-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | Istituto Europeo di Oncologia S.r.l. (IT) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086790-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2014-06-12 | — | — | WO | disclosed |
| EP-2740474-A1 | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a | Instituto Europeo di Oncologia S.r.l. (IT) | 2014-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311245-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH CDK2 INHIBITORS IN THE TREATMENT OF CANCER | CDK2, EZH2, CDK6 | KDM1A 16/4885RCOR1 230/4885MAOA 1955/4885 |
| US-20150315126-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | KDM1A, KDM1B, KDM2A | KDM1A 1/4885RCOR1 152/4885MAOA 790/4885 |
| US-20210100800-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | CDK6, KDM1B, KDM6B | KDM1A 7/4885RCOR1 144/4885MAOA 1440/4885 |
| US-11918580-B2 | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | CDK6, KDM1B, KDM6B | KDM1A 7/4885RCOR1 144/4885MAOA 1440/4885 |
| US-12576083-B2 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | CDK3, CDKN1A, CDKL3 | KDM1A 26/4885RCOR1 587/4885MAOA 3373/4885 |
| US-20240342178-A1 | COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | KDM1B, DOT1L, EZH2 | KDM1A 10/4885RCOR1 106/4885MAOA 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.